ABVC BioPharma, Inc.
ABVC
NASDAQ·Healthcare·Biotechnology·Mkt cap $25.0M
$0.96
▼ -3.99%
P/E
-70.60
Mkt Cap
$25.0M
52-Wk Range
$0.71–$3.40
52-Week Range
$0.71 - $3.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 64.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified pipeline spanning multiple therapeutic areas
- Strategic partnerships with biotech innovators
- Clinical-stage assets with near-term milestones
- Parent company backing from YuanGene Corporation
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Turning profitable
Advancement of clinical trials toward FDA approval
Value
Valuation data unavailable
Momentum
Falling
-28.4% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ABVC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 16, 2026
AUG 12, 2026
Reported EPS of -$0.03 vs -$0.40 consensus (+92.5% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+92.5%
Revenue trend · last 8Q
—
—
-100%
-100%
+104%
-304%
—
—
Q2 24
Q3 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$117.1K
$389.3K
$0
$0
$796.0K
-$796.0K
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ABVC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related